Today, we received a letter from the United States. Dr. Hyla Cass, M.D., and Dr. Susanne Bennett are oncologists at the Santa Monica Health Medical Center in California, with over a decade of clinical experience in using low-molecular-weight citrus pectin (MCP) as an adjunctive therapy for mid-to-late-stage cancer patients.
On March 10, 2019, we met them at the *Natural Products Expo West (Anaheim Convention Center Main Halls)* and engaged in in-depth discussions about the clinical applications of MCP. Dr. Hyla Cass, M.D., shared that based on their decade-long clinical experience, MCP has demonstrated significant inhibitory effects on cancers such as lung, colorectal, gastric, and breast cancers. Particularly during chemotherapy or radiotherapy, MCP serves as a supportive treatment, markedly improving patients' quality of life and clinical outcomes. Our team introduced the technical specifications of our newly developed high-purity MCP product in detail. The two doctors sampled the *Kesaire MCP* on-site and praised its taste, water solubility, purity, and other properties. After carefully comparing it with similar U.S. products in terms of technical parameters and physical characteristics, they concluded that our high-purity MCP outperformed others in taste, transparency, purity, and molecular weight distribution.
Before departing, the two doctors requested samples for further testing and reiterated their eagerness to collaborate soon. The meeting concluded with a cheerful group photo with our team.
